Analyst Summary: Prime Medicine, a biotech company focused on delivering one-time curative genetic therapies, shared its Q4 and full-year 2022 financial results, reporting a net loss of $18 million. The company also announced the successful upsized initial public offering that raised $199 million in gross proceeds, and the selection of PM359 as its first development candidate for the treatment of chronic granulomatous disease. CEO Keith Gottesdiener stated, "we designed and optimized PM359 to achieve high efficiency and highly precise editing of hematopoietic stem cells (HSC) and have observed long-term in vivo engraftment of Prime Edited HSCs in a mouse model of CGD." The company also revealed preclinical proof-of-concept data that suggests Prime Editing's restoration of genetic function, and preliminary safety analyses that demonstrate minimal or no off-target editing in preclinical models. Based on current operating plans, the company expects its cash, cash equivalents, and short-term investments to fund its anticipated operating expenses and capital expenditure requirements into 2025. Forward-looking statements include advancing its broader portfolio toward additional preclinical proof-of-concept readouts, different genome editing technologies, regulatory filings, and licensing agreements.